 |
Dépôt minimal $50 Promotion exclusive |
Notre score |
Commission 0% |
Are you looking to buy ClovOncology stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:CLVS! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about ClovOncology stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Volume moyen
9.01 million shs
CAP DE MARCHÉ
$857.58 million
Bourse
NASDAQ
Achetez cette action !
|
NOM
|
TICKER
|
INDUSTRIE
|
SECTEUR
|
VOLUME
|
ACHETEZ CETTE ACTION MAINTENANT
|
|---|---|---|---|---|---|
|
NASDAQ:CLVS
|
Préparations pharmaceutiques
|
Médical
|
217,504 shs
|
Below is a quick guide on how to buy NASDAQ:CLVS stocks safe, fast and around the world in less than five minutes.
Étape 1 : Ouvrir un compte chez eToro – eToro is the best broker to buy ClovOncology shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Étape 2 : Téléchargez votre ID - Conformément à la réglementation KYC, eToro vous demandera de télécharger une copie de votre passeport ou de votre permis de conduire.
Étape 3 : Dépôt des fonds - Déposez de l'argent sur votre compte eToro nouvellement créé. Vous pouvez choisir entre un virement bancaire, un portefeuille électronique, une carte de débit/crédit ou Paypal.
Étape 4 : Buy ClovOncology – Search for “”NASDAQ:CLVS”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought ClovOncology stocks with 0% commission!.
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
6 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Clovis Oncology in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
Wall Street analysts have given Clovis Oncology a “Hold” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Clovis Oncology wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
2 |  | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
3 |  | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:CLVS stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy ClovOncology stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy ClovOncology stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Comme eToro est une plateforme réglementée, vous devrez remplir le processus KYC, c'est une pratique standard et cela ne prend que quelques minutes. Vous devrez fournir une pièce d'identité avec photo (passeport, permis de conduire) et un justificatif de domicile (facture d'électricité, relevé bancaire).
Une fois que vous vous êtes inscrit et que vous avez vérifié votre compte, vous devrez déposer des fonds. eToro accepte les cartes de crédit/débit, les virements bancaires et également les portefeuilles électroniques. Donc, quelle que soit votre préférence, il y aura quelque chose pour vous.
Now that you’ve funded your eToro account, just type “NASDAQ:CLVS stocks" dans la barre de recherche en haut de l'écran et appuyez sur "commerce".
All that’s left is to buy some NASDAQ:CLVS stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:CLVS is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy ClovOncology stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.12. The biopharmaceutical company had revenue of $38.77 million for the quarter, compared to analysts’ expectations of $42.34 million.
View Clovis Oncology’s earnings history.
Clovis Oncology’s stock was trading at $6.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLVS stock has increased by 54.9% and is now trading at $9.56.
Clovis Oncology issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:CLVS stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Plus de 95% des fonds des clients sont conservés hors ligne, en chambre froide, ce qui est crucial pour tout courtier qui gère vos actifs. Quel que soit le degré de sécurité d'une plateforme, nous vous recommandons d'utiliser le 2FA pour ajouter une couche supplémentaire de sécurité à votre compte.
eToro offre aux utilisateurs une série de fonctionnalités pour commencer à investir le plus rapidement possible. Ils ont une fonction relativement unique appelée copy trading, qui vous permet de gagner un revenu passif en reproduisant des traders expérimentés, cela vous permet de commencer à gagner du profit rapidement, et vous donne une meilleure compréhension des stratégies utilisées par les professionnels. De plus, eToro permet aux utilisateurs d'investir dans des portefeuilles gérés, un portefeuille géré étant une variété d'actifs similaires regroupés, vous permettant de diversifier votre compte, réduisant ainsi tout risque potentiel. Pour ceux qui ont déjà une expérience du trading, vous pouvez investir dans des marchés autres que les actions, car eToro permet aux utilisateurs de négocier des ETF, des matières premières, des crypto et des indices. Si vous investissez déjà en dehors de l'espace boursier, cela peut être très utile, car cela vous permet de gérer tous vos investissements en un seul endroit.
6 brokerages have issued 1-year price objectives for Clovis Oncology’s shares. Their forecasts range from $3.00 to $17.00. On average, they expect Clovis Oncology’s stock price to reach $9.20 in the next twelve months. This suggests that the stock has a possible downside of 3.8%.
View analysts’ price targets for Clovis Oncology or view top-rated stocks among Wall Street analysts.
Clovis Oncology’s management team includes the following people:
Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Les CFD sont des instruments complexes et comportent un risque élevé de perdre rapidement de l'argent en raison de l'effet de levier. 68% des comptes d'investisseurs particuliers perdent de l'argent lorsqu'ils négocient des CFD avec ce fournisseur. Vous devez vous demander si vous comprenez le fonctionnement des CFD et si vous pouvez vous permettre de prendre le risque élevé de perdre votre argent.
12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology’s employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of CLVS’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).
Clovis Oncology trades on the NASDAQ under the ticker symbol “CLVS.”
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
Clovis Oncology’s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. (0.60%), Gamco Investors INC. ET AL (0.36%), Gabelli Funds LLC (0.18%), Dupont Capital Management Corp (0.05%) and SG Americas Securities LLC (0.05%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology.
CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., SG Americas Securities LLC, Pinnacle Associates Ltd., Aperio Group LLC, Vigilare Wealth Management, Dupont Capital Management Corp, and Koshinski Asset Management Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding.
View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks.
CLVS stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Koshinski Asset Management Inc., Diversified Trust Co, Pacer Advisors Inc., GWM Advisors LLC, Gamco Investors INC. ET AL, US Bancorp DE, and Gabelli Funds LLC. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks.
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revue de Interactive Brokers, Revue d'eToro, Revue DEGiro, Revue d'AvaTrade, Examen d'IG Markets, Revue des marchés IC, Revue de CMC Markets, Revue Admiral Markets et bien d'autres encore. Lisez l'une des critiques pour tout savoir sur le courtier et commencez à acheter des actions dès maintenant.
One share of CLVS stock can currently be purchased for approximately $9.56.
Clovis Oncology has a market capitalization of $844.33 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.
A Reportlab.org, nous voulons nous assurer que vous disposez de toutes les informations les plus pertinentes sur acheter des actions. Nous vous apportons les meilleurs guides sur le marché boursier avec des critiques personnelles, des informations de fond, des critiques de plateformes, des modes d'emploi et plus encore. Vous voulez obtenir d'autres informations ? Alors consultez le Actions OTC, Actions du NASDAQ, Actions du NYSE, Actions LON, Stocks FRA, Stocks ETR, Stocks EPA, Actions de la TSX ou Actions Amex. Vous cherchez des informations plus détaillées comme Stocks de 5g, actions de biotechnologie, stocks d'or et d'autres informations de notre reportlab.
How can you buy ClovOncology stock on the internet?
You can easily buy ClovOncology stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Une autre option consiste à utiliser un courtier réglementé comme Marchés IC ou Courtiers interactifs. You can an account with these brokers and start buying or trading NASDAQ:CLVS stocks in a safe and complete environment to trade in.
Where to buy ClovOncology stock?
You will first want to find a licensed broker that supports NASDAQ:CLVS stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:CLVS stocks in a safe and complete environment.
Is NASDAQ:CLVS stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:CLVS stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is ClovOncology stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:CLVS is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in ClovOncology stock.
How do you trade ClovOncology stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for ClovOncology stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:CLVS stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell ClovOncology stock?
To sell your NASDAQ:CLVS stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best ClovOncology stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:CLVS stock.
Stephen connaît bien les produits financiers et a notamment une grande passion pour les marchés boursiers et leurs participants. Nous espérons que les informations fournies vous aideront. Quelque chose n'est pas tout à fait clair ? Veuillez laisser vos questions ou commentaires au bas de la page.
| Notre score ★★★★★ | |
| Notre score ★★★★★ | |
| Notre score ★★★★★ |
Bulletin d'information
Nouvelles récentes
| |
Notre score |
Commission 0% |
Données en temps réel sur les actions et les crypto-monnaies
Notifications, conseils et actualités
Guides des meilleures actions et crypto
Critiques sur les courtiers et les bourses en ligne
Reportlab Finance est un site purement informatif et n'implique en aucun cas des conseils en matière d'investissement. Tous les investissements comportent des risques et vous pouvez perdre tous vos investissements. N'investissez pas l'argent que vous ne pouvez pas vous permettre de perdre.
Reportlab Finance
38 Holburn Lane
Heckfield Green
IP21 0UB
Royaume-Uni
Copyright © 2022 Reportlab.Finance | Tous droits réservés.
